A bispecific scFv against CD3 and CD19, known as blinatumomab (Blincyto), is approved for the treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia [34]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.